Q-omics provides the consensus-scored TSN profile across patient tissues and cancer cell-line models. TSN expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TSN is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TSN RNA expression shows 20,156 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where TSN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSN survival associations across molecular data types. TSN RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSN RNA expression–survival associations across cancer types. High TSN expression shows unfavorable associations in ACC, LIHC, MESO, KIRP and SCLC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TSN RNA expression.
This table summarizes TSN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TSN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSN shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LIHC, COAD and STAD. The HNSC box plot shows higher TSN RNA expression in tumor versus normal tissue (log2 FC = +1.058, t-test p < 0.001).
This table shows molecular features associated with TSN in patient tissues and cancer cell lines. In patient samples, TSN shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TSN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
